Skip to main content
. 2016 Feb 19;11(Spec Iss):21–30. doi: 10.2147/COPD.S85978

Figure 4.

Figure 4

Annual rate of exacerbations, systemic corticosteroid prescriptions, and hospitalizations in a randomized, placebo-controlled trial of combination therapy with a long-acting β-agonist and inhaled corticosteroid in patients with COPD.

Notes: *Significant difference vs placebo at the 0.05 significance level. From The New England Journal of Medicine, Calverley PM, Anderson JA, Celli B, et al, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease, Volume 356(8), Pages 775–789. Copyright © 2007 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.48